[1] |
陈孝平,汪建平.外科学[M].8版.北京:人民卫生出版社,2013:585-587.
|
[2] |
Klan R,Loy V,Huland H.Residual tumur discovered inroutine second transurethral resection in patients with stage T1transitional cell carcinoma of the bladder[J].J Urol,2015,170(2):316-318.
|
[3] |
Herr HW.The value of a second transurethral resection inevaluating patients with bladder tumers[J].J Urol,1999,162(1):74-76.
|
[4] |
Kolozsy Z.Histopathological“self control”in transurethral resection of bladder tumers[J].Bju Int,2016,73(2):162-164.[5]Schenk-Braat EA,Bangmach T.Immunotherapy for superficial bladder cancer[J].Cancer Immunol Immunother,2005,54(5):414-423.
|
[6] |
Sylvester RJ,Osterlinck W,Witjes J.The schedule and duration of intravesical chemotherapy in patients with non muscle invasive bladder cancer:a systematic review of the published results of randomized clinical trials[J].Eur Urol,2017,153(4):709-719.
|
[7] |
孙宏斌,刘军,苏江浩,等.比柔比星膀胱灌注预防浅表性膀胱癌术后复发[J].临床泌尿外科杂志,2002,6(17):284-285.
|
[8] |
那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南(2014 版)[J].北京:人民卫生出版社,2014:55-57.
|
[9] |
Peng GH,Wei Q,Guan J,et al.A systematic review of epirubicin for prevention of postoperative recurrence of superficial bladder cancer[J].Chin J Evidence-Based Med,2016,14(6):382-388.
|
[10] |
Matamura Y,Tsushima T,Ozaki Y,et al.Intravesical chemotherapy with 4′-epiadriamycin in patients with superficial bladder tumours[J].Cancer Chemother Pharmacol,2016,9(8):323-325.
|
[11] |
Theodoulou M,Hudis C.Cardiac profiles of liposomal anthracyclines:greater cardiac safety versus conventional doxorubicin[J].Cancer,2015,100(10):2052-2063.
|
[12] |
Bielack SS,Erttmann R,Kempf-Bielack B,et al.Impact of scheduling on toxicity and clinical efficacy of Doxorubicin:what do we know in the mid-nineties?[J].Eur J Cancer,2006,52(10):1652-1660.
|
[13] |
Matsumura Y,Maeda H.A new concept for macromolecular therapeutics in cancer chemotherapy:mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs[J].Cancer Res,2016,46(12):6387-6392.
|
[14] |
谢雨礼,苏红.抗肿瘤药物多柔比星脂质体[J].药学与临床研究杂志,2010,18(2):107-109.
|
[15] |
Tyagi P,Wu PC,Chancellor M,et al.Recent advances in intravesical drug/gene delivery[J].Mol Pharm,2016,3(4):369-379.
|
[16] |
Adolphss HD,Bastian HP.Chemoimmune prophylaxis of superficial bladder cancer[J].J Urol,2015,229(8):29-33.
|